Aromatase inhibitors increased risk of heart disease in postmenopausal women with breast cancer
2010-12-10
(Press-News.org) SAN ANTONIO — Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.
These data, presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, indicate that women presenting with breast cancer treatment who have risk factors for cardiovascular disease should be considered for a shorter duration of use of aromatase inhibitors.
"It appears that aromatase inhibitors have a significant increase in cardiotoxic side effects, such as heart attack, angina and heart failure," said Eitan Amir, M.D., a senior fellow in the division of medical oncology and hematology at the Princess Margaret Hospital, Toronto, Canada.
Because some cancers, especially breast cancers, require estrogen to grow and spread, drugs that block estrogen production are often used to treat the disease. Tamoxifen blocks the effect of estrogen in breast tissue, whereas aromatase inhibitors prevent the production of estrogen.
Each class of drugs also have related adverse effects. For example, although tamoxifen blocks estrogen production in breast tissue, it has the opposite effect in uterine tissue. Previous research has shown that extended use of tamoxifen results in a small increase in the risk for endometrial cancer and venous thrombosis.
On the other hand, in December 2008, the Food and Drug Administration added a warning label to anastrozole, an aromatase inhibitor, which indicated potential increased risk for heart disease. For this reason, Amir and colleagues conducted a meta-analysis to determine if this increased risk for heart disease occurred with the use of any aromatase inhibitor.
The researchers examined data from seven large randomized clinical trials that compared tamoxifen with aromatase inhibitors in postmenopausal women with early-stage breast cancer.
Data from the analysis confirmed that any duration of use of an aromatase inhibitor was associated with a 20 percent higher probability of developing cardiovascular disease. However, use of aromatase inhibitors also resulted in a reduced risk for venous thrombosis and endometrial carcinoma.
As a secondary analysis, they determined if switching from treatment with tamoxifen to aromatase inhibitors had any effect on mortality or adverse effects. Results showed that the risk for serious adverse effects were similar when aromatase inhibitors were used as an initial treatment compared with switching to aromatase inhibitors after treatment with tamoxifen.
"However, it appears from the data — and this is strictly hypothesis-generating — that if a woman switches from one drug to another, there is a reduction in the risk from death from causes other than breast cancer," Amir said. "This potentially suggests that there may be side effects that build up the longer a woman is on a certain drug, but switching drugs may reduce the side effects."
###
Follow the AACR on Twitter @AACR, and throughout the meeting using the hash tag #SABCS.
Recordings of the teleconferences and video interviews with researchers will posted to the AACR website throughout the meeting: http://www.aacr.org/page23506.aspx.
The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, and the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 33rd annual symposium is expected to draw nearly 9,000 participants from more than 90 countries.
END
ELSE PRESS RELEASES FROM THIS DATE:
2010-12-10
SAN ANTONIO — Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients – those with estrogen receptor (ER)-positive/HER2-negative disease.
About one third of all adults in the United States are obese, posing a major public health problem because of obesity's association with an increased risk of diabetes and heart disease. This study indentified a new hazard associated with obesity.
Results ...
2010-12-10
SAN ANTONIO — Only half of eligible women in the United States are getting their annual mammograms, even if they have insurance to pay for the procedure, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
Last year the U.S. Preventive Services Task Force, an independent panel of non-federal experts in prevention and evidence-based medicine, recommended that the age of first mammogram be lifted from 40 to 50 years of age, at which biennial mammography begins, and caused a public outcry. To date, no major insurance company or other ...
2010-12-10
SAN ANTONIO — While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk, according to study results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.
"Our analysis suggests that, contrary to previous thinking, there is substantial value in bringing HRT with estrogen alone to the guidelines. The data show that for selected ...
2010-12-10
SAN ANTONIO — The long-awaited results of the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer, the AZURE trial, will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 8-12.
"Adjuvant use of bisphosphonates like zoledronic acid is widespread among women with breast cancer, and the results of this trial will help answer many questions as well invite new ones," said Robert Coleman, M.D., professor of medical oncology at the University of Sheffield in England.
Coleman will present the results of AZURE during ...
2010-12-10
SAN ANTONIO — Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer.
In the first head-to-head adjuvant clinical trial comparing two aromatase inhibitors, anastrozole and exemestane, the drugs resulted in similar survival rates and prevention of breast cancer recurrences. Some differences in the side effect profile were seen, including a potential difference in the risk of developing osteoporosis.
Paul E. Goss, M.D., Ph.D., professor ...
2010-12-10
Scientists have sequenced the genome of a major fungal disease that affects barley and other cereal crops, a breakthrough that could lead to significant advances in our understanding of how plant diseases evolve. The research, published today in the journal Science, suggests that parasites within the genome of the fungus help the disease to adapt and overcome the plant's defences.
The study could help with the development of new agricultural techniques for protecting cereal crops from infection. Barley grains are the basis of many staple foods, and also central to the ...
2010-12-10
New research reveals that the abundance of so-called highly siderophile, or metal-loving, elements like gold and platinum found in the mantles of Earth, the Moon and Mars were delivered by massive impactors during the final phase of planet formation over 4.5 billion years ago. The predicted sizes of the projectiles, which hit within tens of millions of years of the giant impact that produced our Moon, are consistent with current planet formation models as well as physical evidence such as the size distributions of asteroids and ancient Martian impact scars. They predict ...
2010-12-10
Norwich scientists are on the trail of some of the most economically damaging organisms that infect crops worldwide. Their latest targets are the parasitic water fungus that causes powdery mildew and the water molds that cause late blight in potatoes and tomatoes and downy mildew in cruciferous vegetables and other crops.
"We have been studying the late blight pathogen for a while," said Professor Sophien Kamoun, head of the Sainsbury Laboratory on the Norwich Research Park. "In separate research we are trialling plant genes that mediate blight resistance, while in this ...
2010-12-10
A team of scientists led by Melissa Rolls, an assistant professor of biochemistry and molecular biology at Penn State University, has peered inside neurons to discover an unexpected process that is required for regeneration after severe neuron injury. The process was discovered during Rolls's studies aimed at deciphering the inner workings of dendrites -- the part of the neuron that receives information from other cells and from the outside world. The research will be published in the print edition of the scientific journal Current Biology on 21 December 2010.
"We already ...
2010-12-10
PITTSBURGH—If you're looking to lose weight, it's okay to think about eating your favorite candy bar. In fact, go ahead and imagine devouring every last bite — all in the name of your diet.
A new study by researchers at Carnegie Mellon University, published in Science, shows that when you imagine eating a certain food, it reduces your actual consumption of that food. This landmark discovery changes the decades-old assumption that thinking about something desirable increases cravings for it and its consumption.
Drawing on research that shows that perception and mental ...
LAST 30 PRESS RELEASES:
[Press-News.org] Aromatase inhibitors increased risk of heart disease in postmenopausal women with breast cancer
